Oncotargets in different renal cancer subtypes

Holger Moch, Rodolfo Montironi, Antonio Lopez-Beltran, Liang Cheng, Axel Mischo

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Renal cell cancer is a heterogeneous group of cancers with different histologic subtypes. The majority of renal tumors in adults are clear cell renal cell carcinomas, which are characterized by von Hippel- Lindau (VHL) gene alterations. Recent advances in defining the genetic landscape of renal cancer has shown the genetic heterogeneity of clear cell renal cell carcinomas (ccRCC) and the presence of at least 3 additional ccRCC tumor suppressor genes on chromosome 3p. Due to inactivation of VHL, renal cancer cells produce the HIF-responsive growth factor VEGF. The PI3K--mTORC1 signaling axis also represents a target for therapy. The new systemic therapies, including tyrosine kinase inhibitors, monoclonal antibodies, and mTOR inhibitors, aim to suppress angiogenesis with vascular endothelial growth factor as a target. Various VEGF-inhibitors are approved for the treatment of ccRCC and we discuss recent advancements in the treatment of metastatic ccRCC. Other gene alterations have been identified in hereditary cancer syndromes, e.g. FLCN, TSC1, TSC2, TFE3, TFEB, MITF, FH, SDHB, SDHD, MET, and PTEN and we review their role in renal tumor carcinogenesis, prognosis, and targeted therapy. By reviewing the associations between morphologic features and molecular genetics of renal cancer we provide insight into the basis for targeted renal cancer therapy.

Original languageEnglish (US)
Pages (from-to)125-135
Number of pages11
JournalCurrent Drug Targets
Volume16
Issue number2
StatePublished - 2015

Fingerprint

Kidney Neoplasms
Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Tumors
Genes
Cells
Chromosomes
Phosphatidylinositol 3-Kinases
Protein-Tyrosine Kinases
Intercellular Signaling Peptides and Proteins
Hereditary Neoplastic Syndromes
Monoclonal Antibodies
Kidney
Neoplasms
Genetic Heterogeneity
Therapeutics
Tumor Suppressor Genes
Molecular Biology
Carcinogenesis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Moch, H., Montironi, R., Lopez-Beltran, A., Cheng, L., & Mischo, A. (2015). Oncotargets in different renal cancer subtypes. Current Drug Targets, 16(2), 125-135.

Oncotargets in different renal cancer subtypes. / Moch, Holger; Montironi, Rodolfo; Lopez-Beltran, Antonio; Cheng, Liang; Mischo, Axel.

In: Current Drug Targets, Vol. 16, No. 2, 2015, p. 125-135.

Research output: Contribution to journalArticle

Moch, H, Montironi, R, Lopez-Beltran, A, Cheng, L & Mischo, A 2015, 'Oncotargets in different renal cancer subtypes', Current Drug Targets, vol. 16, no. 2, pp. 125-135.
Moch H, Montironi R, Lopez-Beltran A, Cheng L, Mischo A. Oncotargets in different renal cancer subtypes. Current Drug Targets. 2015;16(2):125-135.
Moch, Holger ; Montironi, Rodolfo ; Lopez-Beltran, Antonio ; Cheng, Liang ; Mischo, Axel. / Oncotargets in different renal cancer subtypes. In: Current Drug Targets. 2015 ; Vol. 16, No. 2. pp. 125-135.
@article{6b41b2352d844c0ab022d0d2000e5e89,
title = "Oncotargets in different renal cancer subtypes",
abstract = "Renal cell cancer is a heterogeneous group of cancers with different histologic subtypes. The majority of renal tumors in adults are clear cell renal cell carcinomas, which are characterized by von Hippel- Lindau (VHL) gene alterations. Recent advances in defining the genetic landscape of renal cancer has shown the genetic heterogeneity of clear cell renal cell carcinomas (ccRCC) and the presence of at least 3 additional ccRCC tumor suppressor genes on chromosome 3p. Due to inactivation of VHL, renal cancer cells produce the HIF-responsive growth factor VEGF. The PI3K--mTORC1 signaling axis also represents a target for therapy. The new systemic therapies, including tyrosine kinase inhibitors, monoclonal antibodies, and mTOR inhibitors, aim to suppress angiogenesis with vascular endothelial growth factor as a target. Various VEGF-inhibitors are approved for the treatment of ccRCC and we discuss recent advancements in the treatment of metastatic ccRCC. Other gene alterations have been identified in hereditary cancer syndromes, e.g. FLCN, TSC1, TSC2, TFE3, TFEB, MITF, FH, SDHB, SDHD, MET, and PTEN and we review their role in renal tumor carcinogenesis, prognosis, and targeted therapy. By reviewing the associations between morphologic features and molecular genetics of renal cancer we provide insight into the basis for targeted renal cancer therapy.",
author = "Holger Moch and Rodolfo Montironi and Antonio Lopez-Beltran and Liang Cheng and Axel Mischo",
year = "2015",
language = "English (US)",
volume = "16",
pages = "125--135",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Oncotargets in different renal cancer subtypes

AU - Moch, Holger

AU - Montironi, Rodolfo

AU - Lopez-Beltran, Antonio

AU - Cheng, Liang

AU - Mischo, Axel

PY - 2015

Y1 - 2015

N2 - Renal cell cancer is a heterogeneous group of cancers with different histologic subtypes. The majority of renal tumors in adults are clear cell renal cell carcinomas, which are characterized by von Hippel- Lindau (VHL) gene alterations. Recent advances in defining the genetic landscape of renal cancer has shown the genetic heterogeneity of clear cell renal cell carcinomas (ccRCC) and the presence of at least 3 additional ccRCC tumor suppressor genes on chromosome 3p. Due to inactivation of VHL, renal cancer cells produce the HIF-responsive growth factor VEGF. The PI3K--mTORC1 signaling axis also represents a target for therapy. The new systemic therapies, including tyrosine kinase inhibitors, monoclonal antibodies, and mTOR inhibitors, aim to suppress angiogenesis with vascular endothelial growth factor as a target. Various VEGF-inhibitors are approved for the treatment of ccRCC and we discuss recent advancements in the treatment of metastatic ccRCC. Other gene alterations have been identified in hereditary cancer syndromes, e.g. FLCN, TSC1, TSC2, TFE3, TFEB, MITF, FH, SDHB, SDHD, MET, and PTEN and we review their role in renal tumor carcinogenesis, prognosis, and targeted therapy. By reviewing the associations between morphologic features and molecular genetics of renal cancer we provide insight into the basis for targeted renal cancer therapy.

AB - Renal cell cancer is a heterogeneous group of cancers with different histologic subtypes. The majority of renal tumors in adults are clear cell renal cell carcinomas, which are characterized by von Hippel- Lindau (VHL) gene alterations. Recent advances in defining the genetic landscape of renal cancer has shown the genetic heterogeneity of clear cell renal cell carcinomas (ccRCC) and the presence of at least 3 additional ccRCC tumor suppressor genes on chromosome 3p. Due to inactivation of VHL, renal cancer cells produce the HIF-responsive growth factor VEGF. The PI3K--mTORC1 signaling axis also represents a target for therapy. The new systemic therapies, including tyrosine kinase inhibitors, monoclonal antibodies, and mTOR inhibitors, aim to suppress angiogenesis with vascular endothelial growth factor as a target. Various VEGF-inhibitors are approved for the treatment of ccRCC and we discuss recent advancements in the treatment of metastatic ccRCC. Other gene alterations have been identified in hereditary cancer syndromes, e.g. FLCN, TSC1, TSC2, TFE3, TFEB, MITF, FH, SDHB, SDHD, MET, and PTEN and we review their role in renal tumor carcinogenesis, prognosis, and targeted therapy. By reviewing the associations between morphologic features and molecular genetics of renal cancer we provide insight into the basis for targeted renal cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84924293132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924293132&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 125

EP - 135

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 2

ER -